FDA Approves TOBA II BTK Pivotal IDE Clinical Study

October 31, 2016 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the U.S. Food and Drug Administration (FDA) granted staged approval for the Company’s Investigational Device Exemption (IDE) application to begin its Tack Optimized Balloon Angioplasty II BTK (“TOBA II BTK”) clinical study. …

FDA Approves TOBA II BTK Pivotal IDE Clinical Study Read More »